Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive content.

WASHINGTON, DC—For high-risk patients with in-stent restenosis (ISR), the Agent drug-coated balloon (DCB) maintains an advantage over uncoated balloon angioplasty alone, according to new 3-year follow ...

The study involved 587 patients whose cancer had returned after previous treatments. Some patients received the standard of care treatment, and others received the new combination treatment of ...

This deduction is only available to those 65 and older with valid Social Security numbers. Married couples must file a joint return to claim the deduction. High earners may be eligible for a reduced ...

Remote-first AI coding startup Kilo doesn't think software developers should have to pledge their undying allegiance to any one development environment — and certainly not any one model or harness.

Apple is bringing agentic coding to Xcode. On Tuesday, the company announced the release of Xcode 26.3, which will allow developers to use agentic tools, including Anthropic’s Claude Agent and ...

OpenAI has given software developers a new desktop toy, and judging by the early reactions, it might feel like someone finally handed coders the Swiss Army knife they’ve been dreaming about or the ...

OpenAI Group PBC today released a macOS client for its Codex programming assistant. The launch comes about two months after Claude Code, a competing service from Anthropic PBC, topped $1 billion in ...

Today, OpenAI launched a macOS desktop app for Codex, its large language model-based coding tool that was previously used through a command line interface (CLI) on the web or inside an integrated ...

Checkbox today announced a $23 million Series A, led by Touring Capital, with participation from Peak XV (formerly Sequoia Capital India), Conductive Ventures, Tidal Ventures, Five V Capital, and ...

Ideaya Biosciences Inc. has submitted an IND application to the FDA for IDE-574, a KAT6/7 dual inhibitor with potential to treat hormone receptor-positive breast cancer and lung adenocarcinoma. A ...